Myeloproliferative Neoplasms (MPN)

After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and

Catriona Jamieson, MD, PhD, is a board-certified hematologist with broad clinical expertise in caring for patients with hematologic malignancies. As hematology team leader for the Division of Hematology/Oncology at UC San Diego Health Moores Cancer Center, Dr. Jamieson’s clinical interests include the treatment of myeloproliferative neoplasms including chronic myeloid leukemia (CML), polycythemia vera (PV), myelofibrosis and essential thrombocythemia. She is also the principal investigator on several clinical trials for the treatment of these and related bone marrow disorders.

Dr. Barry Skikne is certified by the American Board of Internal Medicine with a subcertification in hematology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Witwatersrand and completed his residency at Johannesburg Hospital.

Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Malcovati's research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients.